Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LX102
- Development stage
- Phase 3
- Lead developer
- Innostellar Biotherapeutics
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Ophthalmic
01
Overview
LX102 is an investigational gene therapy developed by Innostellar Biotherapeutics for the treatment of neovascular (wet) age-related macular degeneration (nAMD). It is an adeno-associated virus (AAV)-based gene therapy designed to deliver genetic material that modulates vascular endothelial growth factor (VEGF) activity in the eye. The mechanism of action involves both gene transference and antagonism of vascular endothelial growth factor (VEGF) receptor, aiming to inhibit abnormal blood vessel growth associated with wet AMD. Clinical development has reached Phase II trials in China for wet age-related macular degeneration, with ongoing studies evaluating its safety and efficacy[1][2][4][5][7].
- Other names
- LX 102 C 01LX102 C 01LX-102 C 01
02
Targets
VEGFR (VEGFR family)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on LX102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LX102.